Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Oral Lumicitabine in Hospitalized Infants and Young Children With RSV Infection
jRCT2080223706Phase 2
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lumicitabine in respiratory syncytial virus disease (RSV) (3 arms), sponsored by Janssen Pharmaceutical.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2080223706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223706.